Basics Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis. IPO Date: September 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.63B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 2.71% Avg Daily Range (30 D): $0.21 | 1.96% Avg Daily Range (90 D): $0.18 | 1.97% Institutional Daily Volume Avg Daily Volume: 1.73M Avg Daily Volume (30 D): 2.1M Avg Daily Volume (90 D): 1.58M Trade Size Avg Trade Size (Sh.): 170 Avg Trade Size (Sh.) (30 D): 115 Avg Trade Size (Sh.) (90 D): 113 Institutional Trades Total Inst.Trades: 2,394 Avg Inst. Trade: $1.23M Avg Inst. Trade (30 D): $1.58M Avg Inst. Trade (90 D): $1.46M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.29M Avg Closing Trade (30 D): $1.83M Avg Closing Trade (90 D): $1.4M Avg Closing Volume: 129.18K     News Jan 8, 2025 @ 8:35 PM New American College of Rheumatology Guidelines fo... Source: Spherix Global Insights Oct 2, 2024 @ 1:48 PM Corporate and Individual Donations Provide Much-Ne... Source: American Kidney Fund Jun 17, 2024 @ 8:46 AM Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump... Source: Zacks Equity Research May 7, 2024 @ 1:55 PM How Much Upside is Left in Aurinia (AUPH)? Wall St... Source: Zacks Equity Research May 2, 2024 @ 11:10 AM Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, To... Source: Zacks Equity Research Financials   TTM Q2 2025 Q1 2025 Basic EPS $.16 $.17 Diluted EPS $.16 $.16 Revenue $ $ 70.01M $ 62.47M Gross Profit $ $ 62.89M $ 53.89M Net Income / Loss $ $ 21.51M $ 23.34M Operating Income / Loss $ $ 20.08M $ 21.85M Cost of Revenue $ $ 7.12M $ 8.57M Net Cash Flow $ $ -13.43M $ -17.01M PE Ratio     Splits Oct 23, 2013:   1:50